AstraZeneca stock: US sales cuts put cost program in focus
Published on 11/14/2026 at 11:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCost program and pipeline focus
- Reuters reported on November 13 that AstraZeneca cut about 600 US sales positions in respiratory and immunology.
- The company is pursuing annual savings of about 1.5 billion US dollars while aiming to reinvest in its drug pipeline.
- AstraZeneca stock traded at 167.53 euros on Lang & Schwarz on Saturday morning.
AstraZeneca is reshaping its US commercial organization as it seeks to reduce costs and direct more resources toward its medicines pipeline. Reuters reported on November 13 that the company had cut about 600 positions in its US respiratory and immunology commercial teams.
Restructuring targets commercial costs
The report said the reductions form part of AstraZeneca's three-year cost-saving initiative. Some affected employees are expected to move into other roles within the company, according to the report, which cited people familiar with the matter.
The restructuring follows AstraZeneca's late-October plan to save about 1.5 billion US dollars annually and reinvest in its drug pipeline. The company has set a target of 80 billion US dollars in annual revenue by 2030, while management continues to face investor scrutiny over the strength and timing of future products.
Pipeline remains central
Respiratory and immunology generated 2.5 billion US dollars in third-quarter revenue, representing 16 percent of group revenue, Reuters reported. The changes therefore affect a meaningful commercial area even as AstraZeneca seeks to protect research and development capacity.
AstraZeneca declined to comment on the reported job cuts. For investors, the key issue is whether lower commercial expenses can support pipeline investment without weakening the launch and promotion of established medicines.
AstraZeneca stock traded at 167.53 euros on Lang & Schwarz at 11:33 CET on Saturday, November 14, 2026.
AstraZeneca company facts
- Company: AstraZeneca plc
- ISIN: GB0009895292
- Trading symbol: AZN
- Latest quote: 167.53 euros on Lang & Schwarz, Saturday, November 14, 2026, at 11:33 CET
Investors can follow the latest current market reports for the wider trading environment.
More news and analyses on AstraZeneca stock are available on the company topic page.
